How to treat essential thrombocythemia and polycythemia vera.

Polycythemia vera and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms associated with thrombotic or hemorrhagic complications, and increased risk of transformation to myelofibrosis and acute myeloid leukemia. The main goal of therapy is aimed at preventing vascular events tha...

Descripción completa

Detalles Bibliográficos
Autores: Besses Raebel, Carles, Álvarez Larrán, Alberto
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2016
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/27985
Acceso en línea:http://hdl.handle.net/10230/27985
http://dx.doi.org/10.1016/j.clml.2016.02.029
Access Level:acceso abierto
Palabra clave:Trombocitèmia
Policitèmia vera
Interferó
id ES_d4b3e3d41acda38f7780dc93e97209ca
oai_identifier_str oai:recercat.cat:10230/27985
network_acronym_str ES
network_name_str España
repository_id_str
spelling How to treat essential thrombocythemia and polycythemia vera.Besses Raebel, CarlesÁlvarez Larrán, AlbertoTrombocitèmiaPolicitèmia veraInterferóPolycythemia vera and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms associated with thrombotic or hemorrhagic complications, and increased risk of transformation to myelofibrosis and acute myeloid leukemia. The main goal of therapy is aimed at preventing vascular events that are the leading cause of morbidity and mortality in these patients. Accordingly, risk stratification is the basis for deciding when to treat a patient with cytoreductive therapy. The European LeukemiaNet has developed a series of management recommendations for front-line and second-line therapy to provide the optimal treatment for the individual patient. There is still controversy about the efficacy and safety of several modalities of cytoreductive treatment in the long-term for both diseases and in the use of antiplatelet therapy in ET. The presence of JAK2V617F and CALR mutations in patients with ET has been related to different thrombotic risks, and this will probably lead to different therapeutic approaches in the near future. On the other hand, the near normal life expectancy of these patients makes a careful analysis of the benefits and risks associated with treatment essential. This review provides our current management strategy of patients with polycythemia vera and ET.CB and AA-L received honoraria for educational lectures from Novartis and Shire. This work was supported by Grants 2014 SGR 567, PI13/00557, PI13/00393, and RD012/0036/0004.Elsevier20172016info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/27985http://dx.doi.org/10.1016/j.clml.2016.02.029reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésClinical Lymphoma, Myeloma & Leukemia. 2016 Aug;16 Suppl:S114-23© Elsevier. http://dx.doi.org/10.1016/j.clml.2016.02.029info:eu-repo/semantics/openAccessoai:recercat.cat:10230/279852026-05-29T05:05:01Z
dc.title.none.fl_str_mv How to treat essential thrombocythemia and polycythemia vera.
title How to treat essential thrombocythemia and polycythemia vera.
spellingShingle How to treat essential thrombocythemia and polycythemia vera.
Besses Raebel, Carles
Trombocitèmia
Policitèmia vera
Interferó
title_short How to treat essential thrombocythemia and polycythemia vera.
title_full How to treat essential thrombocythemia and polycythemia vera.
title_fullStr How to treat essential thrombocythemia and polycythemia vera.
title_full_unstemmed How to treat essential thrombocythemia and polycythemia vera.
title_sort How to treat essential thrombocythemia and polycythemia vera.
dc.creator.none.fl_str_mv Besses Raebel, Carles
Álvarez Larrán, Alberto
author Besses Raebel, Carles
author_facet Besses Raebel, Carles
Álvarez Larrán, Alberto
author_role author
author2 Álvarez Larrán, Alberto
author2_role author
dc.subject.none.fl_str_mv Trombocitèmia
Policitèmia vera
Interferó
topic Trombocitèmia
Policitèmia vera
Interferó
description Polycythemia vera and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms associated with thrombotic or hemorrhagic complications, and increased risk of transformation to myelofibrosis and acute myeloid leukemia. The main goal of therapy is aimed at preventing vascular events that are the leading cause of morbidity and mortality in these patients. Accordingly, risk stratification is the basis for deciding when to treat a patient with cytoreductive therapy. The European LeukemiaNet has developed a series of management recommendations for front-line and second-line therapy to provide the optimal treatment for the individual patient. There is still controversy about the efficacy and safety of several modalities of cytoreductive treatment in the long-term for both diseases and in the use of antiplatelet therapy in ET. The presence of JAK2V617F and CALR mutations in patients with ET has been related to different thrombotic risks, and this will probably lead to different therapeutic approaches in the near future. On the other hand, the near normal life expectancy of these patients makes a careful analysis of the benefits and risks associated with treatment essential. This review provides our current management strategy of patients with polycythemia vera and ET.
publishDate 2016
dc.date.none.fl_str_mv 2016
2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/27985
http://dx.doi.org/10.1016/j.clml.2016.02.029
url http://hdl.handle.net/10230/27985
http://dx.doi.org/10.1016/j.clml.2016.02.029
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Clinical Lymphoma, Myeloma & Leukemia. 2016 Aug;16 Suppl:S114-23
dc.rights.none.fl_str_mv © Elsevier. http://dx.doi.org/10.1016/j.clml.2016.02.029
info:eu-repo/semantics/openAccess
rights_invalid_str_mv © Elsevier. http://dx.doi.org/10.1016/j.clml.2016.02.029
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420569892487168
score 15,811543

Similares en LA Referencia